Syros Pharmaceuticals (SYRS) Appoints Deborah Dunsire to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
September 10, 2021 7:30 AM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Companys Board of Directors. Dr. Dunsire is a highly respected industry veteran with more than 30 years of clinical, commercial, and international management experience within the life sciences industry.
Deborah is a phenomenal leader with a track record of creating value through successful development and commercialization of life-changing new therapies for people with cancer and other serious diseases, said Nancy... More
